|Videos|January 23, 2023
Approaches to Neoadjuvant and Adjuvant Immunotherapy for Patients with MIBC
Author(s)Matthew Galsky, MD
Dr Matthew Galsky contemplates how he would use immunotherapy in patients with MIBC, if it were available for use in both the neoadjuvant and adjuvant setting.
Advertisement
Episodes in this series
Advertisement
Related to this article
A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.
The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
2
New ACS Guidelines Push for Earlier Prostate Cancer Screening
3
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
4
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
5